Anbio Biotechnology Class A Ordinary Shares (NNNN) vs Profound Medical Corp. (PROF)
A side-by-side comparison of Anbio Biotechnology Class A Ordinary Shares and Profound Medical Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NNNN
Anbio Biotechnology Class A Ordinary Shares
$4.90HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PROF
Profound Medical Corp.
$6.08HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NNNN vs PROF
growth of $100 · dividends reinvested · last 2yNNNN -16.3% (-8.5%/yr)PROF -11.2% (-5.8%/yr)PROF compounded faster over this window
NNNN PROF
NNNN vs PROF: by the numbers
- •PROF is the larger company ($221M vs $215M market cap).
- •NNNN is profitable (74.06% net margin) while PROF runs a net loss (-171.72%).
Metrics side by side
Valuation
| Metric | NNNN | PROF |
|---|---|---|
| P/S ratio | N/A | 11.62 |
| P/B ratio | 7.13 | 4.44 |
Profitability
| Metric | NNNN | PROF |
|---|---|---|
| Gross margin | 87.24% | 71.79% |
| Operating margin | 66.70% | -256.27% |
| Net margin | 74.06% | -171.72% |
| ROE | 21.24% | -65.59% |
| ROIC | 19.13% | -61.03% |
Growth (annualized)
| Metric | NNNN | PROF |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 16.55% |
| Total return CAGR (5Y) | N/A | -15.23% |
Frequently asked
- Is NNNN or PROF more profitable?
- NNNN runs the higher net margin — NNNN at 74.06% versus PROF at -171.72%.
Go deeper
Dig into the metrics
Anbio Biotechnology Class A Ordinary Shares ROEProfound Medical ROEAnbio Biotechnology Class A Ordinary Shares operating marginProfound Medical operating marginAnbio Biotechnology Class A Ordinary Shares revenue growthProfound Medical revenue growthAnbio Biotechnology Class A Ordinary Shares free cash flowProfound Medical free cash flow
Anbio Biotechnology Class A Ordinary Shares & Profound Medical appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.